Overview

A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis

Status:
Not yet recruiting
Trial end date:
2024-04-06
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3844583 in healthy participants and participants with atopic dermatitis. The study will also assess how fast LY3844583 gets into the blood stream and how long it takes the body to remove it. The study is open to healthy participants and participants with atopic dermatitis. The study will be conducted in three parts and each participant will enroll in one part. The study will last up to 88, 116, and 186 days with 10, 13, and 14 visits for each participant in parts A, B, and C, respectively.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company